trial · primary record
Pembrolizumab injection
Renal Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 22 |
| Primary completion | 2026-10-01 |
| Primary endpoint | Disease Free Survival (DFS) by Investigator's assessment as defined by RECIST 1.1 |
| Registry ID | NCT06005818 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:04.749Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06005818
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.